IOVANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
IOVANCE BIOTHERAPEUTICS, INC.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$14.21+0.59 (+4.33%)
Close on Oct 19, 2026
- Market cap
- $6.40M
- P/E (TTM)
- –
- Dividend yield
- –
Margins
Share of revenue, fiscal years 2011 to 2025
Gross margin
34.3%
Operating margin
-153.1%
Net margin
-148.4%
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|---|---|---|---|---|
| Revenue | +60.6% | – | – | – | |
| Gross profit | +27.5% | – | – | – |
Returns and balance sheet
10 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2016 | FY2020 | FY2025 | Trend |
|---|---|---|---|---|
| Return on equity | -39.0% | -54.3% | -55.5% | |
| Return on assets | -38.1% | -46.6% | -42.9% | |
| Current ratio | 34.12 | 11.59 | 3.20 | |
| Debt to equity | – | – | – | |
| Net debt to EBITDA | – | – | – | |
| Inventory turnover | – | – | 3.4× | |
| Capex to revenue | – | – | 12.8% | |
| Diluted shares | 0M | 0M | 0M |
Where the cash went
Fiscal 2021 to 2025, five years combined
Iovance Biotherapeutics generated $1.54B from operations and spent $125.19M on capital expenditure, dividends and share buybacks. 100% of that went back into the business.
Generated
$1.54B
Used
$125.19M
Capital expenditure$125.19M100%Dividends$00%Share buybacks$00%
DuPont analysis
Return on equity split into margin, efficiency and leverage
Net margin-148.4%
×Asset turnover0.29×
×Equity multiplier1.29×
=Return on equity, FY2025-55.5%
| Fiscal year | Net margin | Asset turnover | Equity multiplier | Return on equity |
|---|---|---|---|---|
| FY2025 | -148.4% | 0.29× | 1.29× | -55.5% |
| FY2024 | -226.8% | 0.19× | 1.31× | -57.5% |
| FY2023 | -37345.4% | 0.00× | 1.33× | -81.9% |
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
3of 8 tests passed in fiscal 2025. Some tests lack the figures they need.
- ProfitableNet income above zero-$390.98M
- Cash generatingOperating cash flow above zero-$302.41M
- Return on assets improvedROA up on the prior year-47.7% → -42.9%
- Earnings backed by cashOperating cash flow above net income-$302.41M vs -$390.98M
- Less leverageLong-term debt to assets fell0.1% → –
- Better liquidityCurrent ratio rose3.74 → 3.20
- No dilutionShare count did not rise0M → 0M
- Gross margin improvedGross margin up on the prior year43.17% → 34.28%
- More efficientAsset turnover rose0.21 → 0.29